Applies to Employer plans.
Depends on your plan's benefitExpanded indications must NOT be restricted from coverage under the patient's pharmacy benefit.
Qualification pathways
You can qualify through any one of these.
OSA with Obesity — Initial Approval
All of:
- Diagnosis of obstructive sleep apnea (OSA)
- Expanded indications are NOT restricted from coverage under the patient's pharmacy benefit
- Patient has had a polysomnography (PSG) or home sleep apnea test
- Patient has an apnea hypopnea index (AHI) ≥ 15 events/hour from baseline (prior to initiation of pharmacotherapy)
- Requested agent is Zepbound
- Patient has a BMI ≥ 30 kg/m2
- Patient does NOT have craniofacial abnormalities that may affect breathing
- Patient does NOT have a diagnosis of Central or Mixed Sleep Apnea with mixed or central apneas/hypopneas ≥ 50%
- Patient does NOT have a diagnosis of Cheyne Stokes Respiration
- Patient does NOT have a diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia
- Prescriber is a specialist (e.g., pulmonologist, sleep specialist) or has consulted with a specialist
- Patient will NOT use the requested agent in combination with another weight loss agent
- Patient is currently on and will continue weight management regimen (low-calorie diet, increased physical activity, behavioral modifications)
- Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
- Patient does NOT have any FDA labeled contraindications
- Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction
Documentation to bring
- Medical records documenting diagnosis of obstructive sleep apnea (OSA)
- Results of polysomnography (PSG) or home sleep apnea test showing AHI ≥ 15 events/hour from baseline (prior to pharmacotherapy initiation)
- Documentation of BMI ≥ 30 kg/m2
- Documentation ruling out: craniofacial abnormalities affecting breathing, Central or Mixed Sleep Apnea with ≥ 50% central/mixed apneas-hypopneas, Cheyne Stokes Respiration, Obesity Hypoventilation Syndrome or daytime hypercapnia
- Documentation of specialist involvement (pulmonologist or sleep specialist) or consultation
- Documentation of formulary alternatives tried and failed (at least 3), or clinical reason alternatives are contraindicated/less effective/harmful
Approval and renewal
- Initial approval: 12 months
- Renewal: every 12 months
- Renewal: At renewal: patient must have had clinical benefit with the requested agent (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). Specialist requirement is re-verified. AHI ≥ 15 threshold is NOT re-verified at renewal — only clinical benefit is required.
Not covered when
- Craniofacial abnormalities that may affect breathing
- Diagnosis of Central or Mixed Sleep Apnea with mixed or central apneas/hypopneas ≥ 50%
- Diagnosis of Cheyne Stokes Respiration
- Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia
- Co-administration with another weight loss agent
- Co-administration with another GLP-1 receptor agonist
- Any FDA labeled contraindications
- Expanded indications restricted from coverage under patient's pharmacy benefit
Policy note: PAP therapy trial is NOT required prior to approval — this is an expanded indication. The policy does not require that PAP therapy be tried or failed. OSA indication requires AHI ≥ 15 events/hour (moderate-to-severe OSA threshold) from baseline prior to pharmacotherapy initiation, confirmed by PSG or home sleep apnea test. Renewal requires clinical benefit (e.g., AHI reduction, Epworth Sleepiness Scale improvement) but does not re-require the baseline AHI ≥ 15 threshold. Managed by Prime Therapeutics.
Policy effective April 1, 2026 · verified June 5, 2026 · source: BCBS Minnesota Employer / Commercial Insurance prior authorization policy · View policy document (PDF)